The latest update is out from Avita Medical (RCEL).
AVITA Medical, Inc. has secured an exclusive five-year agreement with Regenity Biosciences to market, sell, and distribute a collagen-based dermal matrix in the U.S. and possibly other regions, pending FDA approval. The partnership includes a financial commitment of up to $5 million from AVITA, with revenue sharing starting at 50% and increasing to 60%. This strategic alliance promises to enhance AVITA’s product portfolio and potentially extend their market reach upon successful clinical outcomes and regulatory clearance.
For detailed information about RCEL stock, go to TipRanks’ Stock Analysis page.
